Entrada Therapeutics (NASDAQ:TRDA) Insider Sells $398,708.73 in Stock

Key Points

• Natarajan Sethuraman sold 25,907 shares at an average price of $15.39 for total proceeds of $398,708.73, reducing his stake by 10.7% to 216,317 shares; the sale was executed under a pre-arranged Rule 10b5-1 plan.
• Entrada's stock climbed to $15.79 on the day with volume of 426,082 (vs. average 173,892), trading near its 12‑month high of $16.00 and above its 50‑day ($12.72) and 200‑day ($10.75) moving averages.
• The company reported quarterly EPS of ($0.94), beating estimates while revenue missed, analysts forecast a negative full-year EPS (-4.22), and the consensus rating is a Moderate Buy with a $19.00 target.

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) insider Natarajan Sethuraman sold 25,907 shares of the business's stock in a transaction on Monday, May 4th. The stock was sold at an average price of $15.39, for a total value of $398,708.73. Following the completion of the transaction, the insider directly owned 216,317 shares in the company, valued at approximately $3,329,118.63. This represents a 10.70% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Entrada Therapeutics Price Performance

Entrada Therapeutics stock traded up $1.29 on Monday, reaching $15.79. The company's stock had a trading volume of 426,082 shares, compared to its average volume of 173,892. The business's fifty day moving average price is $12.72 and its 200 day moving average price is $10.75. Entrada Therapeutics, Inc. has a twelve month low of $4.93 and a twelve month high of $16.00.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.94) EPS for the quarter, topping analysts' consensus estimates of ($1.32) by $0.38. The company had revenue of $1.30 million for the quarter, compared to analyst estimates of $7.41 million. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%. Equities research analysts forecast that Entrada Therapeutics, Inc. will post -4.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TRDA has been the subject of a number of recent research reports. Wall Street Zen downgraded Entrada Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, March 28th. Weiss Ratings restated a "sell (d)" rating on shares of Entrada Therapeutics in a research report on Friday, March 27th. Cantor Fitzgerald initiated coverage on Entrada Therapeutics in a research report on Wednesday, April 1st. They set an "overweight" rating for the company. HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Entrada Therapeutics in a research report on Wednesday, February 18th. Finally, Oppenheimer boosted their target price on Entrada Therapeutics from $21.00 to $23.00 and gave the stock an "outperform" rating in a research report on Monday, April 6th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $19.00.

Institutional Investors Weigh In On Entrada Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Baker BROS. Advisors LP increased its holdings in Entrada Therapeutics by 4.3% in the fourth quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company's stock valued at $52,148,000 after purchasing an additional 206,911 shares during the last quarter. Wellington Management Group LLP increased its holdings in Entrada Therapeutics by 9.5% in the fourth quarter. Wellington Management Group LLP now owns 1,044,758 shares of the company's stock valued at $10,740,000 after purchasing an additional 90,339 shares during the last quarter. Millennium Management LLC increased its holdings in Entrada Therapeutics by 391.2% in the third quarter. Millennium Management LLC now owns 836,609 shares of the company's stock valued at $4,852,000 after purchasing an additional 666,287 shares during the last quarter. Geode Capital Management LLC increased its holdings in Entrada Therapeutics by 7.2% in the second quarter. Geode Capital Management LLC now owns 631,554 shares of the company's stock valued at $4,245,000 after purchasing an additional 42,479 shares during the last quarter. Finally, State Street Corp increased its holdings in Entrada Therapeutics by 2.0% in the fourth quarter. State Street Corp now owns 508,789 shares of the company's stock valued at $5,230,000 after purchasing an additional 10,174 shares during the last quarter. Institutional investors own 86.39% of the company's stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics NASDAQ: TRDA is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.